Mechanism of action: Dexmethylphenidate balliculeVisual mnemonic: Dexmethylphenidate mascot “A star is Sir” Ball and chain" must be clipped Scantron → methylphenidate product
What it isActive d-enantiomer inhibiting dopamine and norepinephrine reuptake; ADHD.
Why it mattersIt removes the inactive l-enantiomer, allowing a lower milligram burden than racemic methylphenidate.
What it changesAppetite suppression, insomnia, and growth deceleration can limit use. Schedule II; monitor blood pressure and misuse.
BOXED WARNING High potential for abuse and misuse → substance use disorder incl. addiction; CNS-stimulant misuse/abuse can cause overdose and death. Assess abuse risk before prescribing; monitor throughout treatment.
FDA dosing
Population
Start
Target
Max
ADHD — patients new to methylphenidate (or on other stimulants)
Peds ≥6 yr (label dosing text addresses pediatric patients)
2.5 mg BID (5 mg/day), with or without food
Individualized; titrate weekly 2.5–5 mg
20 mg/day (10 mg BID)
ADHD — patients currently on racemic methylphenidate
Peds (per label dosing text)
Half the current total daily methylphenidate dose
Individualized
20 mg/day (10 mg BID)
Titration Weekly (2.5–5 mg increments)
Renal Undefined
Hepatic Undefined
Instructions
BID, doses at least 4 hours apart, with or without food
Reduce dose or discontinue if paradoxical aggravation of symptoms or adverse reactions
Discontinue if no improvement after appropriate dose adjustment over 1 month
Pretreatment: cardiac history/exam and screen for tics/Tourette's and family history
Available strengths
tab 2.5, 5, 10 mg
ER cap 5, 10, 15, 20, 25, 30, 35, 40 mg
Contraindications
Concomitant MAOI treatment, or within 14 days of stopping an MAOI (hypertensive crisis risk)
Cautions
Avoid in serious cardiac disease; increases BP and heart rate — monitor
Long-term growth suppression in peds — monitor growth; interrupt if not growing/gaining as expected
Acute angle-closure glaucoma / increased IOP
Emergence/worsening of tics and Tourette's
Adverse reactions
Peds (≥5% and 2× placebo): abdominal pain, fever, nausea, anorexia
Pregnancy d-enantiomer of methylphenidate; published methylphenidate data have not identified drug-associated risk of major birth defects/miscarriage; possible CNS-stimulant fetal risks; registry available
Lactation Methylphenidate present in milk (infant dose 0.16–0.7% of maternal weight-adjusted dose); no adverse infant reports; monitor breastfed infant